

Original Article

Check for updates

Risk Factors for Gallbladder Stone Formation after Gastric Cancer Surgery

Young-Won Lee 💿 ¹, Amy Kim¹, Minkyu Han², Moon-Won Yoo 🕞 ¹

¹Division of Stomach Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

²Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

ABSTRACT

Purpose: Although an increased incidence of gallbladder (GB) stone formation after gastrectomy has been reported, its etiology remains uncertain. The goal of this study was to explore the incidence of gallstone formation after gastrectomy in gastric cancer patients and investigate the risk factors therein.

Materials and Methods: Medical records of patients who underwent curative gastrectomy, performed by a single surgeon between August 2012 and December 2015 at the Asan Medical Center, were retrospectively reviewed. Baseline characteristics and surgical outcomes, including GB stone gallstone formation after gastrectomy, were analyzed.

Results: Of 561 patients included in the study, 36 presented with GB stone formation after gastrectomy for gastric cancer. The incidence of gallstone formation was 6.4%. The mean interval between gallstone formation and gastrectomy was 21.9 months. In multivariate analyses, the incidence of gallstone formation increased in patients 63 years or older, with greater than 6.2 kg weight loss in the first 6 months after the procedure, a preoperative serum total bilirubin level greater than 0.5 mg/dL, and in patients who did not receive adjuvant chemotherapy.

Conclusions: This study presented risk factors for GB stone formation after gastric cancer surgery, and special attention should be afforded to patients with such risk factors.

Keywords: Cholecystolithiasis; Stomach neoplasms; Gastrectomy; Incidence; Risk factors

INTRODUCTION

Gastric cancer is one of the most common malignancies in Asian countries, including Korea. Gastric cancer patients in Korea now benefit from better prognoses due to early diagnosis, improved surgical techniques, and perioperative management [1-3]. Hence, the quality of life has gained importance due to the extended life expectancies in patients undergoing gastrectomy for gastric cancer. However, some patients further experience gallbladder (GB) stones or combined cholecystitis, necessitating additional surgical management during the follow-up period [4-8]. The etiology or precise mechanism of GB stone formation after gastrectomy for gastric cancer is yet to be discovered, with few studies investigating this issue, even in Korea with its high prevalence of gastric cancer. Previously reported

OPEN ACCESS

Received: Jul 9, 2019 Revised: Sep 11, 2019 Accepted: Oct 7, 2019

Correspondence to

Moon-Won Yoo

Division of Stomach Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. E-mail: medigang@hanmail.net

Copyright © 2019. Korean Gastric Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Young-Won Lee https://orcid.org/0000-0002-2862-4814 Moon-Won Yoo https://orcid.org/0000-0003-0346-9042

Author Contributions

Conceptualization: L.Y.W., K.A., Y.M.W.; Data curation: L.Y.W., H.M., Y.M.W.; Formal analysis: Y.M.W., H.M.; Methodology: L.Y.W., Y.M.W.; Resources: L.Y.W., Y.M.W.; Supervision: Y.M.W.; Validation: Y.M.W.; Visualization: L.Y.W.; Writing - original draft: L.Y.W.; Writing - review & editing: K.A., Y.M.W.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Generated by 🛟 xmlinkpress



risk factors for GB stone formation after gastrectomy included patient sex, age, decreased body mass index (BMI), or type of gastrectomy in accordance with Paik et al. [9] and Park et al. [10], and included variables regarding the implementation of duodenal exclusion during reconstruction or pre-existing diabetes mellitus (DM). Other studies have shown that extensive lymph node dissection is associated with an increased incidence of GB stone formation after gastric cancer surgery [11-14]. Further information and evidence are crucial to establish prophylactic management techniques to mitigate or prevent additional abdominal interventions such as cholecystectomy. The goal of this study was to evaluate the incidence of GB stone formation and investigate the risk factors leading to cholecystectomy after gastrectomy in gastric cancer.

MATERIALS AND METHODS

Patients

A total of 917 patients underwent gastrectomy for gastric cancer performed by a single surgeon at the Division of Stomach Surgery, Asan Medical Center between August 2012 and December 2015. The exclusion criteria included a history of cholecystectomy (n=20), concomitant cholecystectomy during gastrectomy (n=82), segmental resection of stomach (n=47), palliative gastrectomy (n=13), neoadjuvant chemotherapy performed prior to gastrectomy (n=18), combined resection of intraabdominal organs due to multi-primary cancer (n=19), and body weight not checked at routine follow-up (n=157) (**Fig. 1**). Among the 561 patients without any of the exclusion criteria, 36 presented with GB stone formation after



Fig. 1. Algorithm of enrolled patients and each outcome. The figure shows the algorithm of enrolled patients and each outcome including the exclusion criteria of the study. GB = gallbladder.



gastrectomy for gastric cancer. GB stones were detected by evaluation via perioperative scans using ultrasonography (USG) or abdominal computed tomography (CT). The characteristics evaluated were patient sex, age, preoperative height, weight, BMI, body weight change in the first 6 months after gastrectomy, history of previous abdominal operation, previous diagnosis with liver cirrhosis or DM, location of tumor, operation duration, type of surgery (open or laparoscopic), type of gastrectomy and reconstruction (with or without excluded duodenum), extent of lymph nodes dissection, excision of other adjacent organs, presence of postoperative complications, T/N/M staging using the American Joint Committee on Cancer tumor, node, and metastasis (TNM) classification and staging system for gastric cancer, 7th Edition (2010), implementation of adjuvant chemotherapy, preoperative serum cholesterol level, serum alkaline phosphatase (ALP) level, and serum total bilirubin level.

All included patients underwent either open or laparoscopic surgery for distal gastrectomy (DG), total gastrectomy (TG), or pylorus-preserving gastrectomy (PPG) with regional and/or systemic lymph nodes dissection. After gastrectomy, patients also underwent reconstruction with Billroth I (gastroduodenostomy) or Billroth II (gastrojejunostomy) anastomosis, Roux-en-Y or uncut Roux-en-Y for DG, Roux-en-Y esophagojejunostomy for TG, or gastrogastrostomy for PPG. USG and CT scans were used to detect GB stones and related cholecystitis during the follow-up period. Additionally, these imaging studies, mainly used to monitor recurrence or metastasis after gastrectomy, were also useful for detecting GB stones.

Statistics

The cumulative incidence of GB stone formation after gastrectomy was assayed by the Kaplan-Meier method, with differences between each group evaluated by the log-rank test. Categorical variables were compared using the Fisher's exact test and Pearson χ^2 test. Continuous variables were examined using the Student's t-test, and the mean values were assessed using the Mann-Whitney U test. To evaluate risk factors for GB stone formation after gastrectomy in gastric cancer, univariate and multivariate analyses were conducted using the Cox proportional hazards model. P-values less than 0.05 were considered statistically significant. The receiver operating characteristic analysis and Youden's index were used to find the optimal cut-off value. All statistical calculations were performed using IBM SPSS ver. 25 for Windows (IBM Corporation, Armonk, NY, USA).

Ethics statement

The study was approved by the Institutional Review Board (IRB) of the Asan Medical Center and the University of Ulsan College of Medicine. (No. 2019-0465). All procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consents from patients for this retrospective study were waived by the IRB.

RESULTS

The characteristics of the 561 patients are shown in **Table 1**. The median follow-up period was 32.7 months. Among the 561 patients enrolled, 357 were men (63.6%), and 204 were women (26.4%). Thirty-six patients presented with the formation of GB stones, presenting an incidence rate of 6.4% for GB stone formation after gastrectomy for gastric cancer (**Fig. 2A**). The mean interval between gastrectomy and diagnosis of GB stone formation was 21.9 months.



The incidence rate of GB stone formation was significantly higher in patients over 63 years of age. (15.7% vs. 6.7%, P=0.003; **Fig. 2B**).

Initially, the effect of the degree of obesity on GB stone formation after gastrectomy was evaluated by comparing height, weight, BMI, and changes in body weight in the first 6 months

Table 1.	Characteristics	of	patients
----------	-----------------	----	----------

Sex 0.100 Male 329 (627,) 28 (77,8) Age (year) 60.0-11.8 64.9-9.9 0.013 Height (m) 1.6-6.01 1.6-6.01 0.188 Weight (kg) 63.9-11.3 67.7-19.27 0.068 BMI (kg/m) 24.0-23.4 25.0-23.9 0.0167 Body weight change within 6 months 4.92.4.6 6.7-5.5 0.037 Affer gastrectomy 77.19 0.779 0.799 No 412 (78.5) 27 (75.0) 0.799 No 508 (96.8) 35 (97.2) 0.214 Lver cirrhosis	Characteristics	GB stone negative (n=525)	GB stone positive (n=36)	P-value
Male 329 (62.7) 28 (77.8) Female 196 (37.3) 06 (22.2) Age (year) 60.0=11.8 64.9=9.9 0.013 Height (R) 1.6=0.1 1.6=0.1 0.188 Weight (R) 63.9=11.3 67.7=12.7 0.068 BMI (kg/m) 24.0=3.4 25.0=3.9 0.167 Body weight change within 6 months 4.8=4.6 6.7=5.1 0.037 after gastreetory 7 77.50 7 Previous abdominal operation 77.32.7 0.79 7 No 412 (78.5) 9.72 (75.0) 7 Previous abdominal operation 7 77.50 7 No 412 (78.5) 9 (25.0) 7 7 No 455 (86.7) 28 (7.78) 7 7 0.571 Yees 70 (13.3) 8 (22.2) 0.275 7 0.571 0.571 0.571 0.571 0.571 0.571 0.571 0.571 0.571 0.571 0.571 0.501 0.55.6) 0.00.	Sex			0.100
Fenale 196 (37.3) 08 (22.2) Age (year) 60.0-11.8 64.3±9.9 0.013 Age (year) 1.6±0.1 1.6±0.1 0.183 Height (fm) 1.6±0.1 1.6±0.1 0.183 Weight (kg) 63.9±11.3 67.7±12.7 0.068 BM (kg/m) 24.0±3.4 25.0±3.9 0.167 Body weight change within 6 months 4.8±4.6 6.7±5.1 0.037 after gastrectomy 7 7 0.779 No No 412 (78.5) 27 (75.0) 20.999 No 508 (96.8) 35 (97.2) 21.428 DM 7 (3.2) 1 (2.8) 0.214 No 455 (96.7) 28 (77.8) 20.999 No 450 (96.8) 35 (97.2) 21.428 DM 0 (013) 8 (22.2) 0.214 No 450 (96.7) 28 (78.9) 0.851 Open 235 (44.8) 15 (41.7) 0.851 Open store st	Male	329 (62.7)	28 (77.8)	
Age (year) 60.0±1.8 64.9±9.9 0.013 Height (m) 1.6±0.1 1.6±0.1 0.188 Weight (kg) 63.9±1.3 67.7±1.7 0.068 BM (kg/m) 24.0±3.4 25.0±3.9 0.167 ador weight (kg) 63.9±1.3 67.7±1.7 0.068 BM (kg/m) 24.0±3.4 25.0±3.9 0.079 after gastrectomy 0.779 7 0.779 No 412 (78.5) 27 (75.0) 27 Yes 173 (2.1) 9 (25.0) 20 No 508 (96.8) 35 (97.2) 20 Yes 77 (3.2) 1.2.8 0.214 No 455 (86.7) 28 (77.8) 20 Yes 70 (15.3) 8 (22.2) 0 Open 225 (44.8) 15 (41.7) 24 Laparoscopic 220 (55.2) 21 (58.9) 21 Open 225 (44.8) 15 (41.7) 24 Laparoscopic 220 (55.2) 20 (55.6) 20 GG	Female	196 (37.3)	08 (22.2)	
Height (m) 1.6c.0.1 0.188 Weight (kg) 63.9=11.3 677-12.7 0.068 Bell (kg/m ²) 24.0=3.4 25.0=3.3 0.167 Body weight change within 6 months 4.8=4.6 6.7=5.1 0.037 After gastrectomy 77(75.0) 77(75.0) 77(75.0) No 412 (76.5) 27 (75.0) 9(25.0) Liver cirrhosis .0.299 No 508 (96.8) 35 (97.2) No 508 (96.8) 35 (97.2) .0214 No 455 (86.7) 28 (77.8) .0.214 No 255 (41.8) 15 (41.7) .0.214 Laparoscopic 290 (55.2) 21 (58.3) .0.271 DG 415 (79.1) 0 (0.0.0) .	Age (year)	60.0±11.8	64.9±9.9	0.013
Weight (kg) 63.9±1.3 67.7±12.7 0.068 BMI (kg/m) 24.0±3.4 25.0±3.9 0.167 after gastrectomy	Height (m)	1.6±0.1	1.6±0.1	0.188
BML (kg/m ²) 24.0:3.4 25.0:3.9 0.167 Body weight change within 6 months 4.8:4.6 6.7:5.1 0.037 after gastrectomy 0.779 No 127.5 27.05.0 Yes 113 (21.5) 9 (25.0) .0.999 No 50.6 (96.8) 35 (97.2) .0.214 No 50.6 (96.8) 35 (27.2) .0.214 No 455 (86.7) 28 (77.8) .0.275 Yes 70 (13.3) 8 (22.2) .0.214 No 455 (86.7) 28 (77.8) .0.851 Opent continue (min) 151.6:26.3 186.4:37.5 0.275 Type of surgery .0.410 .0.214 .0.851 Open 225 (44.8) 15 (41.7) .0.410 Jpe of gastrectomy .0.410 .0.571 .0.410 DG 415 (79.1) 26 (72.2) .0.571 TG 100 (19.1) 10 (27.8) .0.671 GD (Gillroth 1) 26 (50.5) 20 (55.6) .0.691 GD (Gilliroth 1)	Weight (kg)	63.9±11.3	67.7±12.7	0.068
Body weight change within 6 months after gastrectomy 4.8-4.6 6.72-5.1 0.037 No 412 (78.5) 27 (75.0) 1 Yes 113 (21.5) 9 (25.0) 0.999 No 508 (96.8) 55 (97.2) 0.214 Iver cirrhosis 70.32) 1 (2.8) 0.214 No 455 (86.7) 28 (77.8) 0.214 No 455 (86.7) 28 (77.8) 0.214 No 455 (86.7) 28 (77.8) 0.214 Yes 70 (3.3) 8 (22.2) 0.214 Open casts(4.8) 15 (41.7) 1.204 0.214 Laparoscopic 290 (55.2) 21 (58.3) 0.217 TG 100 (19.1) 10 (27.8) 0.211 TG 10 (19.9) 0 (0.0) 0.00 GG (60 (10 (19)) 0 (0.0) 0.221 0.231 TG (10 (Billroth II) 8 (15.5) 0 (0.0) 0.231 RYE J 98 (18.7) 10 (27.8) 0.221 Do Choth 725 (52.4) 90 (55.6)	BMI (kg/m²)	24.0±3.4	25.0±3.9	0.167
Previous abdominal operation 0.779 No 412 (78.5) 27 (75.0) Yes 113 (21.5) 9 (25.0) Liver cirrhosis >0.999 No 508 (96.8) 35 (97.2) Yes 17 (3.2) 1 (2.8) DM 0.214 0.214 No 455 (86.7) 28 (77.8) 0.214 Ves 70 (13.3) 8 (22.2) 0.214 Operation time (min) 161.6=36.3 168.4±37.5 0.275 Opera for surgery 0.255 (44.8) 15 (41.7) 124 Laparoscopic 290 (55.2) 21 (58.3) 0.101 DG 415 (73.1) 66 (72.2) 0.215 TG 100 (19.1) 10 (27.8) 0.771 PPG 100 (19.1) 10 (27.8) 0.61 PPG 10 (1.9) 0 (0.0) 0.00 0.00 GD (Billroth I) 265 (50.5) 20 (55.6) 0 0.61 GD (Billroth I) 265 (50.5) 20 (55.6) 0 0.00	Body weight change within 6 months after gastrectomy	4.8±4.6	6.7±5.1	0.037
No 412 (78.5) 27 (75.0) Yes 113 (21.5) 9 (25.0) Liver cirrhosis >0.999 No 508 (96.8) 35 (97.2) Yes 17 (3.2) 1 (2.8) DM 0.214 0.214 No 455 (96.7) 28 (77.8) Yes 70 (15.3) 8 (22.2) Operation time (min) 161.6-36.3 168.4-437.5 0.275 Type of surgery 0.851 0.024 0.10 Open 235 (44.8) 15 (41.7) 128 Type of surgery 0.100 0.10 0.10 DG 415 (79.1) 26 (72.2) 0.10 TG 100 (19.1) 10 (27.8) 0.10 PPG 10 (1.9) 0 (0.0) 0.00 GG 10 (1.9) 0 (0.0) 0.00 RV-EU 98 (18.7) 10 (0.2) 0.10 DG 412 (26.9) 6 (16.7) 7.14 RV-EU 98 (18.7) 10 (27.8) 0.20 Du	Previous abdominal operation			0.779
Yes 113 (21.5) 9 (25.0) Liver cirrhosis >>0.999 No 508 (96.8) 35 (97.2) Yes 17 (3.2) 1 (2.8) DM -0.214 0 No 455 (86.7) 28 (77.8) Yes 70 (13.3) 8 (22.2) Operation time (min) 16.16.5.36.3 16.84.4:37.5 0.275 Type of surgery -0.851 0.681 0.851 Opera 235 (44.8) 15 (41.7) 12.83 Laparoscopic 290 (52.2) 21 (85.3) 10.01 TG 100 (19.1) 10 (27.8) 0.410 PPG 10 (1.9) 0 (0.0) 0 Type of reconstruction 0.571 60 (8illorth 1) 8 (1.5) 0 (0.0) GG (10 (1.9) 0 (0.0) 0 0 10 Uper of reconstruction 0.661 0 (0.0) 0 10 10 10 10 10 10 10 10 10 10 10 10 10 <t< td=""><td>No</td><td>412 (78.5)</td><td>27 (75.0)</td><td></td></t<>	No	412 (78.5)	27 (75.0)	
Liver cirrhosis 508 (96.8) 35 (97.2) No 508 (96.8) 35 (97.2) Yes 77 (3.2) 1 (2.8) DM 0, 455 (86.7) 28 (77.8) Yes 70 (13.3) 8 (22.2) Operation time (min) 161.6::36.3 168.4::37.5 0.275 Type of surgery 0, 235 (44.8) 15 (41.7) Laparoscopic 290 (55.2) 21 (58.3) Type of gastrectomy 0, 415 (79.1) 26 (72.2) TG 100 (19.1) 10 (27.8) PPG 10 (1.9) 0 (0.0) Type of reconstruction 0, 571 GD (Gillroth 1) 265 (50.5) 20 (55.6) GG 10 (1.9) 0 (0.0) Type of reconstruction 0, 571 GD (Gillroth 1) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 14 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) DD defate exclusion 0, 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lympr node dissection* 0, 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lympr node dissection* 0, 275 (52.4) 20 (55.6) Tumor location 0, 275 (52.4) 13 (30.6) DD of D1+ 77 (14.7) 11 (30.6) DD of D2+ 448 (85.3) 25 (69.4) Tumor location 0, 275 (52.7) 15 (41.7) Tumor location 0, 275 (52.7) 15 (41.7) Tumor location 0, 275 (52.8) 12 (58.8) Tumor location 0, 275 (52.9) 10 (27.8) Entrie 8 (1.5) 0 (0.0) Tumor size (cm) 3.8-2.9 2.7±1.2 0.034 T stage* 0, 012 T 1 364 (69.3) 34 (44.4) T 2 50 (9.5) 12.83 T 3 62 (18.8) 11 (28.8) T 4 49 (9.3) 0 (0.0) No. of metastatic lymph nodes 40.0±157 0, 33.8±13.6 0.0141 No. 0, of metastatic lymph nodes 40.0±157 0, 33.8±13.6 0.0141	Yes	113 (21.5)	9 (25.0)	
No 508 (96.8) 35 (97.2) Yes 17 (3.2) 1 (2.8) DM 0.214 No 455 (86.7) 28 (77.8) Yes 70 (13.3) 8 (22.2) Openation time (min) 161.6-36.3 186.4-37.5 0.275 Type of surgery 0.851 0.261 Open 225 (44.8) 15 (41.7) 14 Laparoscopic 290 (55.2) 21 (58.3) 0.410 DG 415 (73.1) 26 (72.2) 0.410 DG 415 (73.1) 26 (72.2) 0.00 TG 100 (19.1) 10 (27.8) 0.60.0 PPG 10 (1.9) 0 (0.0) 0.571 GD (Billroth II) 8 (1.5) 0 (0.0) 0.00 RV-EJ 98 (18.7) 10 (27.8) 0.6167) RV-EJ 98 (18.7) 10 (27.8) 0.6167) Duodenal exclusion 0.241 0.022 0.10 (1.4) Lymph node dissection* 0.206 0.206 D2 or D2+ 448 (85.3)	Liver cirrhosis			>0.999
Yes 17 (3.2) 1 (2.8) DM 0.214 No 455 (86.7) 28 (7.8) Yes 70 (13.3) 8 (22.2) Operation time (min) 161.6=26.3. 168.4=37.5 0.275 Type of surgery 0.851 0.851 0.851 Open 235 (44.8) 15 (41.7) 14 paroscopic 290 (55.2) 21 (58.3) Type of gastrectomy 0.410 0.278 PPG 0.00 100 (19.1) 10 (27.8) PPG PPG 100 (19.1) 0 (27.8) 0.571 GD (Billroth 1) 8 (1.5) 0 (0.0) 0.571 GD (Billroth 1) 8 (1.5) 0 (0.0) 0.60.0 100 (19.1) 0 (27.8) 10 (27.8) Row en-Y 3 (0.6) 0 (0.0) 0.60.0 10 (19.0) 0 (0.0) 10 (19.0) 0 (0.0) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) 10 (27.8) </td <td>No</td> <td>508 (96.8)</td> <td>35 (97.2)</td> <td></td>	No	508 (96.8)	35 (97.2)	
DM 0.214 No 455 (86.7) 28 (77.8) Yes 70 (13.3) 8 (22.2) Operation time (min) 161.6±36.3 168.4±37.5 0.275 Open 235 (44.8) 15 (41.7) 0.851 Open 239 (55.2) 21 (58.3) 0.410 DG 415 (79.1) 26 (72.2) 0.410 TG 10 (19.1) 10 (027.8) PPG PPG 10 (1.9) 0 (0.0) 0 (0.0) Type of reconstruction 0.571 0.600 0.571 GD (Billroth II) 265 (50.5) 20 (55.6) 0.600 GJ (Billroth II) 8 (1.5) 0 (0.0) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) 0.844 No 275 (52.4) 20 (55.6) 20 (55.6) Yes 280 (87.7) 11 (30.6) 0.020 Uordenal exclusion	Yes	17 (3.2)	1 (2.8)	
No 455 (86.7) 28 (7.8) Yes 70 (13.3) 8 (22.2) Operation time (min) 161.6.3.6.3 168.4.37.5 0.275 Type of surgery 0.851 0.261 0.261 Open 225 (44.8) 15 (41.7) Laparoscopic 290 (55.2) 21 (58.3) Type of gastrectomy 0.410 0.667 0.410 DG 415 (79.1) 26 (72.2) 76 TG 100 (19.1) 10 (27.8) 0.60.0 PPG 100 (1.9) 0 (0.0) 0.571 GD (Billroth 1) 265 (55.5) 20 (55.6) 66 GG 10 (1.9) 0 (0.0) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) 0.202 No 275 (52.4) 20 (55.6) 9 Yes 250 (47.6) 16 (4.4) 0.202 Duodenal exclusion 0.2844 (85.3) 25 (69.4) 0.202 Yes 250 (75.7) 15	DM			0.214
Yes 70 (13.3) 8 (22.2) Operation time (min) 161.6±36.3 186.4±37.5 0.275 Type of surgery 0.851 0.975 Open 235 (44.8) 15 (41.7) 1.235 Laparoscopic 290 (55.2) 21 (58.3) 0.410 DG 415 (79.1) 26 (72.2) 0.410 TG 100 (19.1) 10 (27.8) PPG PG 100 (19.1) 0 (0.0) 0.571 GD (Gillforth 1) 265 (50.5) 20 (55.6) GG GG (Sillforth 1) 8 (1.5) 0 (0.0) 0.571 GD (Gillforth 1) 8 (1.5) 0 (0.0) 0.00 Roux-en-Y 3 (0.6) 0 (0.0) 0.844 No 275 (52.4) 20 (55.6) 0.202 Upper node dissection* 0.202 0.216 0.216 Vers 250 (47.6) 16 (44.4) 0.202 Upper Note dissection* 0.206 0.206 Lower 287 (54.7) 15 (41.7) 0.206 Lower	No	455 (86.7)	28 (77.8)	
Operation time (min) 161.6±36.3 168.4±37.5 0.275 Type of surgery 0.851 0.851 Open 235 (44.8) 15 (41.7) Laparoscopic 290 (55.2) 21 (58.3) Type of gastrectomy 0.410 DG 415 (79.1) 26 (72.2) TG 100 (19.1) 10 (27.8) PPG 100 (19.9) 0 (0.0) Type of reconstruction 0.571 GD (8illroth 1) 265 (50.5) 20 (55.6) GG 10 (1.9) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) RV-EJ 98 (18.7) 10 (27.8) Point flow 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymp node dissection* 0.206 Lower 287 (54.7) 11 (30.6) D1 or D1+ 77 (14.7) 11 (30.6) Upper 99 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) <t< td=""><td>Yes</td><td>70 (13.3)</td><td>8 (22.2)</td><td></td></t<>	Yes	70 (13.3)	8 (22.2)	
Type of surgery 0.851 Open 235 (44.8) 15 (41.7) Laparoscopic 290 (55.2) 21 (58.3) Type of gastrectomy 0.410 DG 415 (79.1) 26 (72.2) TG 100 (19.1) 10 (27.8) PPG 10 (1.9) 0 (0.0) Type of reconstruction 0.571 GD (Billroth I) 265 (50.5) 20 (55.6) GG 10 (1.9) 0 (0.0) GJ (Billroth II) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.202 D1 or D1+ 77 (14.7) 11 (30.6) Upper 287 (54.7) 15 (41.7) Middle 15 (28.8) 11 (30.6) Upper 9 (1.1) 10	Operation time (min)	161.6±36.3	168.4±37.5	0.275
Open 235 (44.8) 15 (41.7) Laparoscopic 290 (55.2) 21 (58.3) Type of gastrectomy 0.410 DG 415 (79.1) 26 (72.2) TG 100 (19.1) 10 (27.8) PPG 100 (19.1) 10 (27.8) PPG 100 (1.9) 0 (0.0) GD (Billroth I) 265 (50.5) 20 (55.6) GG 10 (1.9) 0 (0.0) GJ (Billroth II) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) Upper 287 (54.7) 15 (41.7) Middle 15 (28.8) 11 (30.6) Upper 287 (54.7) 10 (27.8) Entrie 8 (1.5)	Type of surgery			0.851
Laparoscopic 290 (55.2) 21 (58.3) Type of gastrectomy 0.410 DG 415 (79.1) 26 (72.2) TG 100 (19.1) 10 (27.8) PPG 10 (1.9) 0 (0.0) Type of reconstruction 0.571 0.600 GD (Billroth I) 265 (50.5) 20 (55.6) 0 GJ (Billroth II) 8 (1.5) 0 (0.0) 0 GJ (Billroth II) 8 (1.5) 0 (0.0) 0 Uncut Roux-en-Y 3 (0.6) 0 (0.0) 0 Uncut Roux-en-Y 141 (26.9) 6 (16.7) 0 RY-EJ 98 (18.7) 10 (27.8) 0 Dudenal exclusion 0.844 0 0.202 No 275 (52.4) 20 (55.6) 9 Yes 250 (47.6) 16 (44.4) 0.022 Up or D1+ 77 (14.7) 11 (30.6) 0.206 Lower 287 (54.7) 15 (41.7) 0.206 Lower 287 (54.7) 10 (27.8) 0.012 Time	Open	235 (44.8)	15 (41.7)	
Type of gastrectomy 0.410 DG 415 (79.1) 26 (72.2) TG 100 (19.1) 10 (27.8) PPG 10 (1.9) 0 (0.0) Type of reconstruction 0.571 0.571 GD (Billroth 1) 265 (50.5) 20 (55.6) 0 GJ (Billroth 1) 8 (1.5) 0 (0.0) 0 GJ (Billroth 1I) 8 (1.5) 0 (0.0) 0 GU (Billroth 1I) 8 (1.5) 0 (0.0) 0 Uncut Roux-en-Y 3 (0.6) 0 (0.0) 0 Uncut Roux-en-Y 141 (26.9) 6 (16.7) 7 RY-EJ 98 (18.7) 10 (27.8) 0 Duodenal exclusion 0.844 0 0.844 No 275 (52.4) 20 (55.6) 0 Yes 250 (47.6) 16 (44.4) 0 Lymph node dissection* 0.206 0 0 D1 or D1+ 77 (14.7) 11 (30.6) 0 0 D2 or D2+ 448 (85.3) 25 (69.4) 0 0<	Laparoscopic	290 (55.2)	21 (58.3)	
DG 415 (79.1) 26 (72.2) TG 100 (19.1) 10 (27.8) PPG 10 (1.9) 0 (0.0) Type of reconstruction 0.571 GD (Billroth I) 265 (50.5) 20 (55.6) GG 10 (1.9) 0 (0.0) GJ (Billroth II) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) U2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entrice 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 <	Type of gastrectomy			0.410
TG 100 (19.1) 10 (27.8) PPG 10 (1.9) 0 (0.0) Type of reconstruction 0.571 GD (Billroth I) 265 (50.5) 20 (55.6) GG 10 (1.9) 0 (0.0) GJ (Billroth II) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Dudenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entrice 8 (1.5) 0 (0.0) Tumor location 0.012 0.012 Tot size (cm) 3.8±2.9 2.7±1.2 0.034 Tatage* 0.012 0.021 0.021 T1	DG	415 (79.1)	26 (72.2)	
PPG 10 (1.9) 0 (0.0) Type of reconstruction 0.571 0.60 GD (Billroth I) 265 (50.5) 20 (55.6) GG 10 (1.9) 0 (0.0) GJ (Billroth II) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Uwer 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entric 8 (1.5) 0 (0.0) Tumor size (cm) 3.8+2.9 2.7±1.2 0.034 T stage* 0 (0.5) 1 (2.8) T3 62 (11.8) 1 (2.8) <tr< td=""><td>TG</td><td>100 (19.1)</td><td>10 (27.8)</td><td></td></tr<>	TG	100 (19.1)	10 (27.8)	
Type of reconstruction 0.571 GD (Billroth I) 265 (50.5) 20 (55.6) GG 10 (1.9) 0 (0.0) GJ (Billroth II) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8+2.9 2.7±1.2 0.034 T stage* 0 (0.0) 10 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (PPG	10 (1.9)	0 (0.0)	
GD (Biltroth I) 265 (S0.5) 20 (S5.6) GG 10 (1.9) 0 (0.0) GJ (Biltroth II) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 1 1 T1 364 (69.3) 34 (94.4) 1 T2 50 (9.5) 1 (2.8) 1 T3 62 (11.8)	Type of reconstruction		o o (== o)	0.571
GG 10 (1.9) 0 (0.0) GJ (Billroth II) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.842.9 2.7±1.2 0.034 T stage* 0.012 0.012 11 T3 62 (11.8) 1 (2.8) 1 T4 49 (9.3) 0 (0.0) 1 No. of retrieved lymph nodes 40.0±15.7	GD (Billroth I)	265 (50.5)	20 (55.6)	
GJ (Biltroth II) 8 (1.5) 0 (0.0) Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 11 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) 1 12.8) T3 62 (11.8) 1 (2.8) 1 12.8) T4 49 (9.3) 0 (0.0) 14	GG	10 (1.9)	0 (0.0)	
Roux-en-Y 3 (0.6) 0 (0.0) Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 0.11 T1 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014	GJ (Billroth II)	8 (1.5)	0 (0.0)	
Uncut Roux-en-Y 141 (26.9) 6 (16.7) RY-EJ 98 (18.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 11 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) 1 12.8) T3 62 (11.8) 1 (2.8) 1 14.9 T4 49 (9.3) 0 (0.0) 1 14.9 14.9	Roux-en-Y	3 (0.6)	0 (0.0)	
RY-EJ 98 (8.7) 10 (27.8) Duodenal exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 0.11 0.012 T1 364 (69.3) 34 (94.4) 12 T2 50 (9.5) 1 (2.8) 12 T3 62 (11.8) 1 (2.8) 14 T4 49 (9.3) 0 (0.0) 10 No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014	Uncut Roux-en-Y	141 (26.9)	6 (16.7)	
Duodenat exclusion 0.844 No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 0.012 T1 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014	RY-EJ	98 (18.7)	10 (27.8)	0.044
No 275 (52.4) 20 (55.6) Yes 250 (47.6) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 012 T1 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014		075 (50.4)	00 (55 c)	0.844
res 250 (47.8) 16 (44.4) Lymph node dissection* 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 0.012 0.012 T1 364 (69.3) 34 (94.4) 12 T2 50 (9.5) 1 (2.8) 1 T3 62 (11.8) 1 (2.8) 1 T4 49 (9.3) 0 (0.0) 1 No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	NO	275 (52.4)	20 (55.6)	
Lympin node dissection 0.022 D1 or D1+ 77 (14.7) 11 (30.6) D2 or D2+ 448 (85.3) 25 (69.4) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 0.012 T1 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	ies	250 (47.6)	16 (44.4)	0.000
D1 01 D1+ D2 or D2+ T/ (14.7) T1 (30.6) Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 0.012 T1 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036		77 (14 7)	11 (20 6)	0.022
Tumor location 0.206 Lower 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 0.012 TI 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014	Dior Di+	// (14./)	II (30.0)	
Initial focation 287 (54.7) 15 (41.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 0.012 TI 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.2±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	Dz 01 Dz+	440 (03.3)	25 (69.4)	0.906
Lower 257 (94.7) 15 (94.7) Middle 151 (28.8) 11 (30.6) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 0.012 TI 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036		007 (54 7)	15 (417)	0.200
Induce In (20.0) Upper 79 (15.1) 10 (27.8) Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 TI 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	Middle	207 (34.7)	13 (41.7)	
Entire 8 (1.5) 0 (0.0) Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 TI 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	Upper	79 (15 1)	10 (97.8)	
Tumor size (cm) 3.8±2.9 2.7±1.2 0.034 T stage* 0.012 T1 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	Entire	8 (1 5)	0 (0 0)	
T stage* 0.012 T1 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	Tumor size (cm)	3 8+2 9	9 7+1 9	0.034
TI 364 (69.3) 34 (94.4) T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.2±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	T stage*	0.0-2.0	2.7-1.2	0.012
T2 50 (9.5) 1 (2.8) T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	T1	364 (69.3)	34 (94,4)	01012
T3 62 (11.8) 1 (2.8) T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	Т2	50 (9.5)	1 (2.8)	
T4 49 (9.3) 0 (0.0) No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	T3	62 (11.8)	1 (2.8)	
No. of retrieved lymph nodes 40.0±15.7 33.8±13.6 0.014 No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	T4	49 (9.3)	0 (0.0)	
No. of metastatic lymph nodes 2.2±7.1 0.2±0.7 0.036	No. of retrieved lymph nodes	40.0±15.7	33.8±13.6	0.014
	No. of metastatic lymph nodes	2.2±7.1	0.2±0.7	0.036

(continued to the next page)

Characteristics	GB stone negative (n=525)	GB stone positive (n=36)	P-value
N stage*			0.429
NO	390 (74.3)	32 (88.9)	
N1	50 (9.5)	3 (8.3)	
N2	36 (6.9)	1 (2.8)	
N3a	24 (4.6)	0 (0.0)	
N3b	25 (4.8)	0 (0.0)	
M stage*			>0.999
MO	524 (99.8)	36 (100.0)	
M1	1 (0.2)	0 (0.0)	
Combined excision of adjacent organs			0.069
No	520 (99.1)	34 (94.4)	
Yes	5 (0.9)	2 (5.6)	
Postoperative complications			0.768
No	475 (90.5)	32 (88.9)	
Yes	50 (9.5)	4 (11.1)	
Postoperative chemotherapy			<0.001
No	345 (65.7)	33 (91.7)	
Yes	180 (34.3)	3 (8.3)	
Preoperative serum cholesterol level (mg/dL)	183.0±40.3	174.6±30.3	0.280
Preoperative serum ALP level (IU/L)	69.2±34.3	71.0±22.4	0.637
Preoperative serum total bilirubin level (mg/dL)	0.6±0.3	0.8±0.4	0.003

Table 1. (Continued) Characteristics of patients

Values are presented as mean±standard deviation or number (%).

GB = gallbladder; BMI = body mass index; DM = diabetes mellitus; DG = distal gastrectomy; TG = total

gastrectomy; PPG = pylorus-preserving gastrectomy; GD = gastroduodenostomy; GG = gastrogastrostomy; GJ = gastrojejunostomy; EJ = esophagojejunostomy; ALP = alkaline phosphatase; TNM = tumor, node, and metastasis. *According to the 7th Union for International Cancer Control/American Joint Committee on Cancer TNM system.

after gastrectomy. No significant differences in height, weight, or BMI were uncovered. However, weight loss after gastrectomy was significantly associated with an increased risk of GB stone formation, with the incidence rate significantly higher in patients who lost more than 6.2 kg (15.5% vs. 7.4%, P=0.002; **Fig. 2C**). Patients who did not undergo postoperative chemotherapy also had a significantly higher incidence of GB stone formation than those who did (13.1% vs. 4.1%, P=0.002; **Fig. 2D**). The incidence of GB stone formation was significantly higher in patients with higher preoperative serum total bilirubin levels (13.4% vs. 3.5%, P=0.003; **Fig. 2E**); the cut-off value for serum total bilirubin level was 0.5 mg/dL.

No significant statistical differences in GB stone formation were observed for the other variables, with the results as follows: sex (P=0.100), height (P=0.188), weight (P=0.068), BMI (P=0.167), previous abdominal operation (P=0.779), liver cirrhosis (P>0.999), DM (P=0.214), operation time (P=0.275), open versus laparoscopic procedure (P=0.851), type of gastrectomy (P=0.410), type of reconstruction after gastrectomy (P=0.571), whether or not the duodenum was excluded (P=0.844), tumor location (P=0.206), N stage and M stage pathology (P=0.429 and P>0.999, respectively), combined resection of adjacent organs or not (P=0.069), postoperative complications (P=0.768), and preoperative serum cholesterol level and ALP levels (P=0.280 and P=0.637, respectively).

Variables associated with significant differences, revealed using univariate analyses, were then evaluated with multivariate analyses using the Cox proportional hazard model, which showed that patient age, weight loss in the first 6 months after the procedure, lack of postoperative chemotherapy, and elevated serum total bilirubin levels were significant risk factors for GB stone formation after gastrectomy for gastric cancer (**Table 2**).





Fig. 2. Graph showing the incidence rate of GB stone formation after gastrectomy for gastric cancer.

(A) Kaplan-Meier analysis of the cumulative incidence of GB stone formation after gastrectomy for gastric cancer. (B) Incidence of GB stone formation after gastrectomy in patients over and under 63 years old (P=0.003). (C) Incidence of GB stone formation after gastrectomy in patients who lost under or over 6.2 kg in the 6 months after the surgery (P=0.002). (D) Incidence of GB stone formation after gastrectomy in patients who did or did not undergo adjuvant chemotherapy and (P=0.002). (E) Incidence of GB stone formation after gastrectomy in patients with relatively higher (≥0.5 mg/dL) or lower serum total bilirubin levels (<0.5 mg/dL) (P=0.003).

GB = gallbladder.



Table 2. Univariate and multivariate analysis of risk factors for GB stone formation after gastrectomy

Variables	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P-value*	HR (95% CI)	P-value
Age	1.037 (1.006–1.068)	0.018	1.047 (1.016–1.079)	0.003
Body weight change within 6 months after gastrectomy	0.923 (0.864–0.986)	0.018	0.890 (0.827–0.957)	0.002
Lymph node dissection [†]				
D1 or D1+	1	Ref	-	-
D2 or D2+	0.332 (0.162–0.681)	0.003	-	-
Combined resection of adjacent organs				
No	1	Ref	-	-
Yes	4.453 (1.064–18.63)	0.041	-	-
Tumor size	0.781 (0.638-0.956)	0.016	-	-
No. of retrieved lymph nodes	0.973 (0.948-0.999)	0.039	-	-
Postoperative chemotherapy				
No	1	Ref	1	Ref
Yes	0.158 (0.048-0.518)	0.002	0.150 (0.045-0.498)	0.002
Preoperative serum total bilirubin level	3.900 (1.773-8.579)	<0.001	3.724 (1.578-8.788)	0.003

GB = gallbladder: HR = hazard ratio: CI = confidence interval: TNM = tumor, node, and metastasis.

*Cox proportional hazards model. [†]According to the 7th Union for International Cancer Control/American Joint Committee on Cancer TNM system.

DISCUSSION

Gastric cancer is one of the most prevalent malignancies in Asia, and particularly in Korea. The quality of life in patients undergoing gastrectomy for gastric cancer has gained significance owing to extended life expectancies associated with early diagnosis and advanced management. Therefore, we retrospectively inspected patient data to discover potential risk factors for GB stone formation in patients after gastrectomy for gastric cancer in order to minimize the likelihood of patients needing additional interventions such as cholecystectomy in the future.

Unlike in previous studies, we observed that risk factors such as obesity, male gender, and exclusion of the duodenum during reconstruction after gastrectomy did not affect the incidence of GB stone formation [9]. Furthermore, no correlation was reported between the incidence of GB stone formation and patient history of DM with Roux-en-Y reconstruction after gastrectomy [11]. Some studies included TG, rather than partial gastrectomy, as a significant factor resulting in the higher incidence of GB stone formation [15]. Conversely, the current study revealed that certain other factors influenced the incidence of GB stone formation after gastrectomy for gastric cancer.

As shown in previous studies, this study confirmed that the incidence of GB stone formation was significantly higher in older patients regardless of whether they underwent gastrectomy or not. The rate of GB stone formation increases with each decade after 20 years of age due to an increased amount of cholesterol in the bile. Moreover, hemoperfusion of the GB wall decreases with age due to sclerotic changes, contributing to GB dysfunction [16-18]. The same is probably true in case of patients undergoing gastrectomy for gastric cancer.

Furthermore, patients who demonstrated greater body weight loss in the 6 months after gastrectomy reported a higher incidence of GB stone formation. Other studies have mentioned a correlation between obesity, as measured by BMI, and showed an association between high BMI and GB stone formation. However, we observed a significant effect associated with weight loss in the 6 months after gastrectomy rather than a particular BMI



value. One of the major pathophysiologic mechanisms of GB stone formation is the hypomotility of the gallbladder, resulting in slower gallbladder emptying, and leading to the precipitation of cholesterol crystals via unstable vesicles [16,19-21]. This mechanism can be observed in patients who lose a great deal of body weight in a shorter period of time. As many obese patients lost a significant amount of weight after gastrectomy for gastric cancer, this study suggests a correlation between significant fluctuations in body weight and a higher incidence of GB stone formation [22].

Interestingly, this study revealed that patients with relatively high levels of preoperative serum total bilirubin presented a higher incidence of GB stone formation after gastrectomy. We propose that the high levels of bilirubin, a major source of GB stones, easily crystallize, especially into brown or black pigmented stones regardless of antecedent gastrectomy. This same principle of GB stone formation might account for the association between high preoperative serum bilirubin levels and higher incidence of GB stone formation after gastrectomy for gastric cancer. To avoid any redundant management such as cholecystectomy following GB stone formation after gastrectomy, it is recommended that patients reduce their serum bilirubin level with ursodeoxycholic acid prior to surgery [23].

There are some limitations to this study. Firstly, this was a retrospectively designed study based on data from a single center. To confirm these outcomes, a prospectively designed study using multicenter data is necessary. Also, the critical serum total bilirubin level resulting in a higher incidence of GB stone formation after gastrectomy was 0.5 mg/dL, which is of little practical significance as the normal serum bilirubin levels ranges from 0.2 to 1.2 mg/dL. In our study, while patients with GB stone formation demonstrated relatively higher serum total bilirubin levels, several patients were within the normal range. We also lacked an adequate population to evaluate potential correlations between postoperative chemotherapy and the incidence of GB stone formation after gastrectomy for gastric cancer. In the current study, significant differences with regard to the incidence of GB stone formation after gastrectomy and adjuvant chemotherapy were uncovered. Thirty-six patients reported GB stone formation; however only 3 out of the total 561 enrolled patients underwent postoperative chemotherapy. Previous studies have suggested that there is no correlation between these 2 factors. However, our results conflicted with previous reports [24]. Next, we will attempt to resolve these differences in an upcoming investigation using a larger population.

In conclusion, multivariate analyses in this study revealed that older patients, patients demonstrating a significant loss in body weight during the first 6 months after gastrectomy, patients receiving no postoperative adjuvant chemotherapy, and patients with relatively high preoperative serum total bilirubin levels present a greater risk for GB stone formation after gastrectomy for gastric cancer. Therefore, special attention should be paid to patients with these indicating risk factors.

REFERENCES

- Ahn HS, Lee HJ, Yoo MW, Jeong SH, Park DJ, Kim HH, et al. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg 2011;98:255-260.
 PUBMED | CROSSREF
- Choi IJ. Gastric cancer screening and diagnosis. Korean J Gastroenterol 2009;54:67-76.
 PUBMED | CROSSREF



- Park CH, Song KY, Kim SN. Treatment results for gastric cancer surgery: 12 years' experience at a single institute in Korea. Eur J Surg Oncol 2008;34:36-41.
 PUBMED I CROSSREF
- Liang TJ, Liu SI, Chen YC, Chang PM, Huang WC, Chang HT, et al. Analysis of gallstone disease after gastric cancer surgery. Gastric Cancer 2017;20:895-903.
 PUBMED | CROSSREF
- Lai SL, Yang JC, Wu JM, Lai IR, Chen CN, Lin MT, et al. Combined cholecystectomy in gastric cancer surgery. Int J Surg 2013;11:305-308.
 PUBMED | CROSSREF
- Hauters P, de Neve de Roden A, Pourbaix A, Aupaix F, Coumans P, Therasse G. Cholelithiasis: a serious complication after total gastrectomy. Br J Surg 1988;75:899-900.
 PUEMED | CROSSREF
- Pezzolla F, Lantone G, Guerra V, Misciagna G, Prete F, Giorgio I, et al. Influence of the method of digestive tract reconstruction on gallstone development after total gastrectomy for gastric cancer. Am J Surg 1993;166:6-10.
 PUBMED | CROSSREF
- Nakamura K, Ogoshi K, Makuuchi H. Clinicopathological study of cholelithiasis following gastric cancer surgery. Eur Surg Res 2005;37:29-35.
 PUBMED | CROSSREF
- Paik KH, Lee JC, Kim HW, Kang J, Lee YS, Hwang JH, et al. Risk factors for gallstone formation in resected gastric cancer patients. Medicine (Baltimore) 2016;95:e3157.
 PUBMED | CROSSREF
- Park DJ, Kim KH, Park YS, Ahn SH, Park J, Kim HH. Risk factors for gallstone formation after surgery for gastric cancer. J Gastric Cancer 2016;16:98-104.
 PUBMED | CROSSREF
- Fukagawa T, Katai H, Saka M, Morita S, Sano T, Sasako M. Gallstone formation after gastric cancer surgery. J Gastrointest Surg 2009;13:886-889.
 PUBMED | CROSSREF
- Wu CC, Chen CY, Wu TC, Iiu TJ, P'eng PK. Cholelithiasis and cholecystitis after gastrectomy for gastric carcinoma: a comparison of lymphadenectomy of varying extent. Hepatogastroenterology 1995.42:867-872.
 PUBMED
- Akatsu T, Yoshida M, Kubota T, Shimazu M, Ueda M, Otani Y, et al. Gallstone disease after extended (D2) lymph node dissection for gastric cancer. World J Surg 2005;29:182-186.
 PUBMED | CROSSREF
- Kodama I, Yoshida C, Kofuji K, Ohta J, Aoyagi K, Takeda J. Gallstones and gallbladder disorder after gastrectomy for gastric cancer. Int Surg 1996;81:36-39.
- Jun KH, Kim JJ, Chin HM, Park SM. Retrospective analysis on the gallstone disease after gastrectomy for gastric cancer. Gastroenterol Res Pract 2015;2015:827864.
 PUBMED | CROSSREF
- Kobayashi T, Hisanaga M, Kanehiro H, Yamada Y, Ko S, Nakajima Y. Analysis of risk factors for the development of gallstones after gastrectomy. Br J Surg 2005;92:1399-1403.
 PUBMED | CROSSREF
- Tompkins RK, Kraft AR, Zimmerman E, Lichtenstein JE, Zollinger RM. Clinical and biochemical evidence of increased gallstone formation after complete vagotomy. Surgery 1972;71:196-200.
 PUBMED
- Wang DQ. Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice. J Lipid Res 2002;43:1950-1959.
 PUBMED | CROSSREF
- Reshetnyak VI. Concept of the pathogenesis and treatment of cholelithiasis. World J Hepatol 2012;4:18-34.
 PUBMED | CROSSREF
- Rehnberg O, Haglund U. Gallstone disease following antrectomy and gastroduodenostomy with or without vagotomy. Ann Surg 1985;201:315-318.
 PUBMED | CROSSREF
- Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Weight cycling and risk of gallstone disease in men. Arch Intern Med 2006;166:2369-2374.
 PUBMED | CROSSREF
- Ura K, Sarna SK, Condon RE. Antral control of gallbladder cyclic motor activity in the fasting state. Gastroenterology 1992;102:295-302.
 PUBMED | CROSSREF



- Inoue K, Fuchigami A, Higashide S, Sumi S, Kogire M, Suzuki T, et al. Gallbladder sludge and stone formation in relation to contractile function after gastrectomy. A prospective study. Ann Surg 1992;215:19-26.
 PUBMED | CROSSREF
- Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 2012;6:172-187.
 PUBMED | CROSSREF